

Ref: MHL/Sec&Legal/2021-22/11

Date: May 27, 2021

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release as mentioned below:


‘Metropolis Healthcare Limited records consolidated revenue of INR 292 Crore in Q4 FY20-21 registering 42% growth YoY.’

You are requested to take the above information on record.

Thanking You,

Yours Faithfully

For **Metropolis Healthcare Limited**



Poonam Tanwani
Company Secretary & Compliance Officer
Membership No. A19182
Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com
Website: www.metropolisindia.com
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd records consolidated revenue of INR 292 crore in Q4FY21 registering 42% growth YoY.

- Q4FY21 PAT at INR 61.3 cr as against INR 15.5 cr in Q4FY20, resulting in a growth of 296% YoY
- FY21 PAT at INR 183.3 cr in FY21 as against INR 127.5 cr in FY20, resulting in a growth of 44% YoY

Mumbai, May 27th 2021: Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its audited consolidated financial results today for (Q4FY21) and (FY21)

We are pleased to post strong Q4 performance, recording our highest ever quarterly revenues driven largely by our NON-COVID business. Metropolis continues to work and support the state governments in the fight against COVID19. Our large capacities and expertise in specialized testing enabled us to seamlessly serve over 8 lakh new customers for COVID tests. COVID tests and COVID allied tests have witnessed an uptick in Q1FY22. Our strong vision for digital transformation, our rich and growing test menu and a relentless pursuit of world-class customer experience has helped us build and grow our B2C revenues in our core markets and will help us gain market share in other key markets for us. We continue to prioritize safety, quality, and hygiene.

Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Ltd

FINANCIAL HIGHLIGHTS

In INR Crs	FY21	FY20	YoY%
Revenue from Operations	997.8	855.5	+17%
EBIDTA	288.0	231.9	+24%
EBIDTA (%)	28.9%	27.1%	+180 bps
Profit After Tax	183.3	127.5	+44%
Profit After Tax (%)	18.4%	14.9%	+350 bps

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah won the prestigious Entrepreneur of the Year Award by EY in Lifesciences and Healthcare category

Metropolis Healthcare won the Leading Diagnostic Chain of the Year award at the Elets Diagnostics Leadership Summit, 2021

Metropolis Healthcare Ltd won the 2020 Indian Diagnostic Services Industry Company of the Year Award organised by Frost & Sullivan.

Metropolis Healthcare won the award for Outstanding Logistics Unit during Pandemic award in the Healthcare Category organised by Supply Chain and Logistics Excellence (SCALE) Awards

Metropolis won five different awards for its CSR Projects from different reputed CSR platforms.

Our CFO, Mr. Rakesh Agarwal was awarded at the 11th Annual CFO Awards for his exceptional contribution to the world of finance.

Our MD, Ms. Ameera Shah has been listed in Asia's Power Businesswomen 2020 by Forbes Asia

OTHER KEY HIGHLIGHTS

Revenue for FY21 increased by 17% YoY despite severe impact in Q1FY21.

Reported EBITDA for FY21 increased by 24% YoY and EBITDA Margins expanded by 180 bps YoY on the back of increased scale of business, strong cost optimization and automation efforts.

PAT for FY21 increased by 44% YoY and PAT Margin expanded by 350 bps YoY.

Crossed Rs. 100cr Revenue mark in March 2021 led by healthy recovery in Non Covid and increased Covid testing on M-o-M basis.

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798 Pvt. Ltd.

Ms. Nadhiya Mali – Corporate Communications

nadhiya.mali@metropolisindia.com

+91-8879009517 www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah shogun.jain@sgapl.net /

shrenik.shah@sgapl.net